Article Text

Download PDFPDF
Extended report
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis
  1. Y P M Goekoop-Ruiterman1,
  2. J K de Vries-Bouwstra2,
  3. P J S M Kerstens3,
  4. M M J Nielen3,
  5. K Vos3,
  6. D van Schaardenburg2,3,
  7. I Speyer4,
  8. P E H Seys5,
  9. F C Breedveld1,
  10. C F Allaart1,
  11. B A C Dijkmans2,3
  1. 1
    Leiden University Medical Centre, Leiden, The Netherlands
  2. 2
    VU Medical Centre, Amsterdam, The Netherlands
  3. 3
    Jan van Breemen Institute, Amsterdam, The Netherlands
  4. 4
    Hospital Bronovo, The Hague, The Netherlands
  5. 5
    Hospital Lievensberg, Bergen op Zoom, The Netherlands
  1. Correspondence to Mrs Y P M Goekoop-Ruiterman, Leiden University Medical Centre, Department of Rheumatology C-1-R, PO Box 9600, 2300 RC Leiden, The Netherlands; y.p.m.goekoop{at}


Objectives: To compare the efficacy of Disease Activity Score (DAS)-driven therapy and routine care in patients with recent-onset rheumatoid arthritis.

Methods: Patients with recent-onset rheumatoid arthritis receiving traditional antirheumatic therapy from either the BeSt study, a randomised controlled trial comparing different treatment strategies (group A), or two Early Arthritis Clinics (group B) were included. In group A, systematic DAS-driven treatment adjustments aimed to achieve low disease activity (DAS ⩽2.4). In group B, treatment was left to the discretion of the treating doctor. Functional ability (Health Assessment Questionnaire (HAQ)), Disease Activity Score in 28 joints (DAS28) and Sharp/van der Heijde radiographic score (SHS) were evaluated.

Results: At baseline, patients in group A (n = 234) and group B (n = 201) had comparable demographic characteristics and a mean HAQ of 1.4. Group A had a longer median disease duration than group B (0.5 vs 0.4 years, p = 0.016), a higher mean DAS28 (6.1 vs 5.7, p<0.001), more rheumatoid factor-positive patients (66% vs 42%, p<0.001) and more patients with erosions (71% vs 53%, p<0.001). After 1 year, the HAQ improvement was 0.7 vs 0.5 (p = 0.029), and the percentage in remission (DAS28 <2.6) 31% vs 18% (p<0.005) in groups A and B, respectively. In group A, the median SHS progression was 2.0 (expected progression 7.0), in group B, the SHS progression was 1.0 (expected progression 4.4).

Conclusions: In patients with recent-onset rheumatoid arthritis receiving traditional treatment, systematic DAS-driven therapy results in significantly better clinical improvement and possibly improves the suppression of joint damage progression.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This study was funded by a grant from the Dutch College of Health Insurances (College Voor Zorgverzekeringen) with additional funding provided by Schering-Plough, BV and Centocor.

  • Competing interests CFA and FCB have received lecture fees from Schering-Plough; BACD has received funds for research and lecture fees from Schering-Plough.

  • Ethics approval Ethics committee approval from all participating centres.

  • Patient consent Patient consent received.